

Welcome to STN International! Enter x:x

LOGINID:ssspta1617srh

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 Apr 09 ZDB will be removed from STN  
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03 New e-mail delivery for search results now available  
NEWS 10 Jun 10 MEDLINE Reload  
NEWS 11 Jun 10 PCTFULL has been reloaded  
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment  
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;  
saved answer sets no longer valid  
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY  
NEWS 15 Jul 30 NETFIRST to be removed from STN  
NEWS 16 Aug 08 CANCERLIT reload  
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 18 Aug 08 NTIS has been reloaded and enhanced  
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 27 Oct 21 EVENTLINE has been reloaded  
NEWS 28 Oct 24 BEILSTEIN adds new search fields  
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN  
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002  
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT  
NEWS 32 Nov 25 More calculated properties added to REGISTRY  
NEWS 33 Dec 02 TIBKAT will be removed from STN  
NEWS 34 Dec 04 CSA files on STN  
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 36 Dec 17 TOXCENTER enhanced with additional content  
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN  
NEWS 38 Dec 30 ISMEC no longer available  
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS  
NEWS 40 Jan 21 NUTRACEUT offering one free connect hour in February 2003  
NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003  
NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,  
ENERGY, INSPEC  
NEWS 43 Feb 13 CANCERLIT is no longer being updated

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,

CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
 AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:54:43 ON 21 FEB 2003

=> il capl  
 IL IS NOT A RECOGNIZED COMMAND  
 The previous command name entered was not recognized by the system.  
 For a list of commands available to you in the current file, enter  
 "HELP COMMANDS" at an arrow prompt (=>).

=> fil capl		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 11:54:50 ON 21 FEB 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Feb 2003 VOL 138 ISS 9  
 FILE LAST UPDATED: 20 Feb 2003 (20030220/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s jonsson, m?/au  
 L1 128 JONSSON, M?/AU

=> s laakso, t?/au  
 L2 100 LAAKSO, T?/AU

=> s l1 and l2

L3 0 L1 AND L2

=> s reslow, m?/au

L4 16 RESLOW, M?/AU

=> s l1 and l4

L5 0 L1 AND L4

=> d ti l4 tot

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2003 ACS

TI Process for producing microparticles containing biologically active substance and PEG

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2003 ACS

TI Parenterally administrable microparticles containing PEG and starch

L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2003 ACS

TI Forming purified starch and microparticles with controlled release of a biologically active substance

L4 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2003 ACS

TI Pharmaceutically acceptable starch

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2003 ACS

TI A controlled-release starch microparticle for parenteral administration

L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2003 ACS

TI Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight

L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2003 ACS

TI Biodegradable controlled release microparticles containing amylopectin-based starch of reduced molecular weight

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2003 ACS

TI Encapsulation method using biodegradable polymers

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2003 ACS

TI Modification of the microenvironment of enzymes in organic solvents. Substitution of water by polar solvents

L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2003 ACS

TI The influence of the support material on enzymic synthesis in organic media

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2003 ACS

TI A potentiometric enzyme electrode for monitoring in organic solvents

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2003 ACS

TI Selection of solvents for bioorganic synthesis

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2003 ACS

TI The influence of water on protease-catalyzed peptide synthesis in acetonitrile/water mixtures

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2003 ACS

TI Organic solvents for bioorganic synthesis. 2. Influence of log P and water solubility in solvents on enzymic activity

L4 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2003 ACS  
 TI On the importance of the support material for bioorganic synthesis.  
 Influence of water partition between solvent, enzyme and solid support in  
 water-poor reaction media

L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2003 ACS  
 TI Organic solvents for bioorganic synthesis. 1. Optimization of parameters  
 for a chymotrypsin catalyzed process

=> d 1-8

L5 HAS NO ANSWERS

L1 128 SEA FILE=CAPLUS ABB=ON PLU=ON JONSSON, M?/AU  
 L4 16 SEA FILE=CAPLUS ABB=ON PLU=ON RESLOW, M?/AU  
 L5 0 SEA FILE=CAPLUS ABB=ON PLU=ON L1 AND L4

=> d l4 1-8 ibib abs

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:391501 CAPLUS  
 DOCUMENT NUMBER: 136:391007  
 TITLE: Process for producing microparticles containing  
 biologically active substance and PEG  
 INVENTOR(S): Reslow, Mats; Joensson, Monica; Laakso, Timo  
 PATENT ASSIGNEE(S): Bioglan AB, Swed.  
 SOURCE: PCT Int. Appl., 42 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002039986	A1	20020523	WO 2001-SE2167	20011005
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SE 2000004217	A	20020517	SE 2000-4217	20001116
SE 518007	C2	20020813		
AU 2001092528	A5	20020527	AU 2001-92528	20011005
US 2002086060	A1	20020704	US 2001-970796	20011005
PRIORITY APPLN. INFO.:				
			SE 2000-4217	A 20001116
			US 2001-260497P	P 20010108
			WO 2001-SE2167	W 20011005
AB A process for producing microparticles contg. biol. active substance, in which process an aq. soln. of the said substance is prepd., this soln. is mixed with an aq. soln. of PEG such that the substance is concd. and/or solidified, the substance is optionally washed, the substance is mixed with an org. polymer soln., the compn. obtained is mixed, after the admixt. of said polymer soln., with an aq. polymer soln., thereby forming an emulsion of droplets of first mentioned polymer as the internal phase,				

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PATENT INFORMATION:

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TITLE: Forming purified starch and microparticles with controlled release of a biologically active substance

INVENTOR(S): Gustafsson, Nils Ove; Berden, Per; Joensson, Monica;

PATENT ASSIGNEE(S): Laakso, Timo; Reslow, Mats  
 SOURCE: Bioglan AB, Swed.  
 PCT Int. Appl., 42 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028909	A1	20020411	WO 2001-SE2168	20011005
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SE 2000003616	A	20020407	SE 2000-3616	20001006
SE 517422	C2	20020604		
AU 2001094460	A5	20020415	AU 2001-94460	20011005
US 2002045745	A1	20020418	US 2001-970648	20011005
US 2002065411	A1	20020530	US 2001-970795	20011005

PRIORITY APPLN. INFO.: SE 2000-3616 A 20001006  
 US 2001-260491P P 20010108  
 WO 2001-SE2168 W 20011005  
 AB Prod. of purified, parenterally administrable starch by washing starch contg. >85% amylopectin to remove surface-localized proteins, lipids and endotoxins, subjecting the starch to a mol. wt. redn. by acid hydrolysis, and optionally removing residual water-sol. proteins.  
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:276034 CAPLUS  
 DOCUMENT NUMBER: 136:296465  
 TITLE: Pharmaceutically acceptable starch  
 INVENTOR(S): Gustavsson, Nils Ove; Berden, Per; Joensson, Monica; Laakso, Timo; Reslow, Mats  
 PATENT ASSIGNEE(S): Bioglan AB, Swed.  
 SOURCE: PCT Int. Appl., 43 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028908	A1	20020411	WO 2001-SE2163	20011005
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

SE 2000003616	A	20020407	SE 2000-3616	20001006
SE 517422	C2	20020604		
AU 2001094457	A5	20020415	AU 2001-94457	20011005
US 2002045745	A1	20020418	US 2001-970648	20011005
US 2002065411	A1	20020530	US 2001-970795	20011005

PRIORITY APPLN. INFO.:

SE 2000-3616	A	20001006
US 2001-260491P	P	20010108
WO 2001-SE2163	W	20011005

AB Prodn. of purified, parenterally administrable starch is accomplished by washing starch contg. more than 85% amylopectin in order to remove surface-localized proteins, lipids and endotoxins, dissolving the starch in aq. medium, mol. wt. redn. by shearing, and optionally removal of residual water-sol. proteins, preferably by anion exchange chromatog.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:275775 CAPLUS

DOCUMENT NUMBER: 136:284479

TITLE: A controlled-release starch microparticle for parenteral administration

INVENTOR(S): Reslow, Mats; Bjoern, Soeren; Drustrup, Joern; Gustafsson, Nils Ove; Joensson, Monica; Laakso, Timo

PATENT ASSIGNEE(S): Bioglan AB, Swed.

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028375	A1	20020411	WO 2001-SE2165	20011005
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SE 2000003614	A	20020407	SE 2000-3614	20001006
SE 517610	C2	20020625		
AU 2001094459	A5	20020415	AU 2001-94459	20011005
US 2002102311	A1	20020801	US 2002-970792	20020110

PRIORITY APPLN. INFO.:

SE 2000-3614	A	20001006
US 2001-260495P	P	20010108
WO 2001-SE2165	W	20011005

AB A parenterally administrable, biodegradable microparticle prepn., preferably composed of amylopectin-contg. starch is described. The prepn. contains a biol. active substance which, during the first 24 h after injection, exhibits a release of the active substance that is less than 25% of the total release, detd. from a concn.-time curve in the form of the ratio between the area under the curve during the said first 24 h and

the total area under the curve in question. For example, bovine serum albumin (BSA) was immobilized with high loading in starch microspheres produced from highly branched, sheared starch. A starch soln. (40%) of sheared, highly branched starch with an av. mol. wt. of 1600 kDa, a soln. of PEG 20,000 Da (38%) and a soln. of BSA (14%) were prepd. in 50 mM sodium phosphate, pH 8.3 and spray dried. The protein yield was 94%, the starch yield 89%, and the loading obtained was 10%. The mean particle size was 98 .mu.m and with less than 10% of the distribution below 35 .mu.m. By incubation with .alpha.-amylase or .alpha.-amylase and amyloglucosidase the microspheres were fully dissolved within 48 h.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:275771 CAPLUS

DOCUMENT NUMBER: 136:299676

TITLE: Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight

INVENTOR(S): Joensson, Monica; Larsson, Karin; Gustafsson, Nils Ove; Laakso, Timo; **Reslow, Mats**

PATENT ASSIGNEE(S): Bioglan AB, Swed.

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028371	A1	20020411	WO 2001-SE2169	20011005
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SE 2000003615	A	20020407	SE 2000-3615	20001006
SE 517421	C2	20020604		
AU 2001092529	A5	20020415	AU 2001-92529	20011005
US 2002044976	A1	20020418	US 2001-970793	20011005
US 2002098203	A1	20020725	US 2002-970794	20020110
PRIORITY APPLN. INFO.:			SE 2000-3615	A 20001006
			US 2001-260455P	P 20010108
			WO 2001-SE2169	W 20011005

AB A vaccine compn. is disclosed which comprises an immunol. active substance embedded in microparticles essentially consisting of starch having an amylopectin content exceeding 85 % by wt., of which at least 80 % by wt. has an av. mol. wt. within the range of 10-10,000 kDa. A process for prepg. such vaccine compn. is also disclosed.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:275770 CAPLUS

DOCUMENT NUMBER: 136:299729



TITLE: Biodegradable controlled release microparticles containing amylopectin-based starch of reduced molecular weight

INVENTOR(S): Joensson, Monica; Gustavsson, Nils Ove; Laakso, Timo; **Reslow, Mats**

PATENT ASSIGNEE(S): Bioglan AB, Swed.

SOURCE: PCT Int. Appl., 62 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028370	A1	20020411	WO 2001-SE2164	20011005
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				
SE 2000003615	A	20020407	SE 2000-3615	20001006
SE 517421	C2	20020604		
AU 2001094458	A5	20020415	AU 2001-94458	20011005
US 2002044976	A1	20020418	US 2001-970793	20011005
US 2002098203	A1	20020725	US 2002-970794	20020110

PRIORITY APPLN. INFO.: SE 2000-3615 A 20001006  
US 2001-260455P P 20010108  
WO 2001-SE2164 W 20011005

AB A process for producing parenterally administrable microparticles, in which an at least 20% by wt. aq. soln. of purified amylopectin-based starch of reduced mol. wt. is prepd., the soln. is combined with a biol. active substance, an emulsion of starch droplets is formed in an outer phase of polymer soln., the starch droplets are made to gel, and the gelled starch particles are dried. A release-controlling shell is optionally also applied to the particles. Microparticles which essentially consist of the starch, have an amino acid content of <50 .mu.g and have no covalent chem. crosslinking. Thus, starch microspheres contg. BSA were produced from highly branched starch with av. mol. wt. of 1930 kDa. The starch soln. was mixed with PEG and the mixt. was administered s.c. and i.m. to rats. The microspheres were biodegraded rapidly within 1 wk, and the tissue is rapidly normalized.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:282075 CAPLUS

DOCUMENT NUMBER: 130:316644

TITLE: Encapsulation method using biodegradable polymers

INVENTOR(S): Laakso, Timo; **Reslow, Mats**

PATENT ASSIGNEE(S): Bioglan Therapeutics AB, Swed.

SOURCE: PCT Int. Appl., 31 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9920253	A1	19990429	WO 1998-SE1717	19980924
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
SE 9703874	A	19990424	SE 1997-3874	19971023
SE 512663	C2	20000417		
CA 2306824	AA	19990429	CA 1998-2306824	19980924
AU 9894670	A1	19990510	AU 1998-94670	19980924
AU 732891	B2	20010503		
EP 1033973	A1	20000913	EP 1998-948005	19980924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2001520186	T2	20011030	JP 2000-516653	19980924
ZA 9809199	A	19990415	ZA 1998-9199	19981008
NO 2000002039	A	20000613	NO 2000-2039	20000418
PRIORITY APPLN. INFO.:			SE 1997-3874	A 19971023
			WO 1998-SE1717	W 19980924

AB This invention provides a novel method of encapsulating an active substance in a biodegradable polymer, which comprises: (a) dissolving the biodegradable polymer in an org. solvent; (b) dispersing the active substance in the org. soln. obtained in step (a) to provide a dispersion with the active substance as the inner phase thereof, or alternatively, emulsifying the active substance, dissolved in water or other aq. solvent, in the org. soln. obtained in step (a) to provide an emulsion with the active substance as the inner aq. phase; and (c) subjecting the dispersion or emulsion to an encapsulation operation with an aq. polyethylene glycol soln. as a continuous phase to provide micro- or nanoparticles having the active substance encapsulated therein. A soln. of glycolide-lactide copolymer was prepd. by dissolving the polymer in EtOAc, then bovine serum albumin dissolved in a phosphate buffer was added to the polymer soln. The obtained homogeneous dispersion was slowly injected into the soln. of polyethylene glycol with stirring. Deionized water was added to reduce the viscosity of the suspension for filtration using a Millipore membrane. The filtrate was washed with water and dried to obtain spherical microparticles.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s joensson, mon?/au  
L6 12 JOENSSON, MON?/AU

=> d his

(FILE 'HOME' ENTERED AT 11:54:43 ON 21 FEB 2003)

FILE 'CAPLUS' ENTERED AT 11:54:50 ON 21 FEB 2003

L1 128 S JONSSON, M?/AU  
L2 100 S LAAKSO, T?/AU  
L3 0 S L1 AND L2  
L4 16 S RESLOW, M?/AU  
L5 0 S L1 AND L4

L6 12 S JOENSSON, MON?/AU

=> s l6 and l4

L7 7 L6 AND L4

=> d ti tot

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI Process for producing microparticles containing biologically active substance and PEG

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI Parenterally administrable microparticles containing PEG and starch

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI Forming purified starch and microparticles with controlled release of a biologically active substance

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI Pharmaceutically acceptable starch

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI A controlled-release starch microparticle for parenteral administration

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS

TI Biodegradable controlled release microparticles containing amylopectin-based starch of reduced molecular weight

=> d 7

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 2002:275770 CAPLUS

DN 136:299729

TI Biodegradable controlled release microparticles containing amylopectin-based starch of reduced molecular weight

IN Joensson, Monica; Gustavsson, Nils Ove; Laakso, Timo; Reslow, Mats

PA Bioglan AB, Swed.

SO PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002028370	A1	20020411	WO 2001-SE2164	20011005
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GD, GE, GR, GM, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,			

	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
SE 2000003615	A	20020407	SE 2000-3615	20001006
SE 517421	C2	20020604		
AU 2001094458	A5	20020415	AU 2001-94458	20011005
US 2002044976	A1	20020418	US 2001-970793	20011005
US 2002098203	A1	20020725	US 2002-970794	20020110
PRAI SE 2000-3615	A	20001006		
US 2001-260455P	P	20010108		
WO 2001-SE2164	W	20011005		

RE.CNT 5      THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 7 full  
 'FULL' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS -----	GI and AB
ALL -----	BIB, AB, IND, RE
APPS -----	AI, PRAI
BIB -----	AN, plus Bibliographic Data and PI table (default)
CAN -----	List of CA abstract numbers without answer numbers
CBIB -----	AN, plus Compressed Bibliographic Data
DALL -----	ALL, delimited (end of each field identified)
DMAX -----	MAX, delimited for post-processing
FAM -----	AN, PI and PRAI in table, plus Patent Family data
FBIB -----	AN, BIB, plus Patent FAM
IND -----	Indexing data
IPC -----	International Patent Classifications
MAX -----	ALL, plus Patent FAM, RE
PATS -----	PI, SO
SAM -----	CC, SX, TI, ST, IT
SCAN -----	CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN)
STD -----	BIB, IPC, and NCL
IABS -----	ABS, indented with text labels
IALL -----	ALL, indented with text labels
IBIB -----	BIB, indented with text labels
IMAX -----	MAX, indented with text labels
ISTD -----	STD, indented with text labels
OBIB -----	AN, plus Bibliographic Data (original)
OIBIB -----	OBIB, indented with text labels
SBIB -----	BIB, no citations
SIBIB -----	IBIB, no citations
HIT -----	Fields containing hit terms
HITIND -----	IC, ICA, ICI, NCL, CC and index field (ST and IT) containing hit terms
HITRN -----	HIT RN and its text modification
HITSTR -----	HIT RN, its text modification, its CA index name, and its structure diagram
HITSEQ -----	HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
FHITSTR -----	First HIT RN, its text modification, its CA index name, and its structure diagram
FHITSEQ -----	First HIT RN, its text modification, its CA index name, its

structure diagram, plus NTE and SEQ fields  
 KWIC ----- Hit term plus 20 words on either side  
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.  
 ENTER DISPLAY FORMAT (BIB):end

=> d 7 all

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS  
 AN 2002:275770 CAPLUS  
 DN 136:299729  
 TI Biodegradable controlled release microparticles containing amylopectin-based starch of reduced molecular weight  
 IN Joensson, Monica; Gustavsson, Nils Ove; Laakso, Timo; Reslow, Mats  
 PA Bioglan AB, Swed.  
 SO PCT Int. Appl., 62 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K009-16  
 ICS A61K009-50; B01J013-02  
 CC 63-6 (Pharmaceuticals)  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002028370	A1	20020411	WO 2001-SE2164	20011005
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	SE 2000003615	A	20020407	SE 2000-3615	20001006
	SE 517421	C2	20020604		
	AU 2001094458	A5	20020415	AU 2001-94458	20011005
	US 2002044976	A1	20020418	US 2001-970793	20011005
	US 2002098203	A1	20020725	US 2002-970794	20020110
PRAI	SE 2000-3615	A	20001006		
	US 2001-260455P	P	20010108		
	WO 2001-SE2164	W	20011005		
AB	A process for producing parenterally administrable microparticles, in which an at least 20% by wt. aq. soln. of purified amylopectin-based starch of reduced mol. wt. is prepd., the soln. is combined with a biol. active substance, an emulsion of starch droplets is formed in an outer phase of polymer soln., the starch droplets are made to gel, and the gelled starch particles are dried. A release-controlling shell is				

optionally also applied to the particles. Microparticles which essentially consist of the starch, have an amino acid content of <50 .mu.g and have no covalent chem. crosslinking. Thus, starch microspheres contg. BSA were produced from highly branched starch with av. mol. wt. of 1930 kDA. The starch soln. was mixed with PEG and the mixt. was administered s.c. and i.m. to rats. The microspheres were biodegraded rapidly within 1 wk, and the tissue is rapidly normalized.

ST amylopectin starch controlled release microparticle

IT Proteins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(C; biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT Freeze drying

Human

Immobilization, molecular

Molecular weight distribution

Particle size distribution

(biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT Blood-coagulation factors

Growth factors, animal

Interleukins

Nucleotides, biological studies

Peptides, biological studies

Polyesters, biological studies

Polymers, biological studies

Polynucleotides

Polyoxyalkylenes, biological studies

Polysaccharides, biological studies

Proteins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT Polymers, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(biodegradable; biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT Polyesters, biological studies

Polyesters, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(hydroxycarboxylic acid-based; biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT Polyesters, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(lactic acid-based; biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT Drug delivery systems

Drug delivery systems

(microparticles, controlled-release; biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT Drug delivery systems

(parenterals; biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT Albumins, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(serum; biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT Drying

(spray; biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT Drying

(vacuum; biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT Interferons  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(.alpha.; biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT Lactoglobulins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(.beta.-; biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT Interferons  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(.beta.; biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT Interferons  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(.gamma.; biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT 9037-22-3, Amylopectin  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Cerestar SF 04201; biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT 9000-90-2, .alpha.-Amylase 9032-08-0, Amyloglucosidase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

IT 7440-66-6D, Zinc, human growth hormone complexes 9001-24-5, Blood coagulation factor V 9001-28-9, Blood coagulation factor IX 9001-29-0, Blood coagulation factor X 9001-30-3, Blood coagulation factor XII 9002-72-6, Growth hormone 9002-72-6D, Somatotropin, zinc complexes 9004-10-8, Insulin, biological studies 9005-25-8, Starch, biological studies 9005-82-7, Amylose 9013-56-3, Blood coagulation factor XIII 9034-40-6D, LHRH, analogs 9035-60-3, Blood coagulation factor VI 11096-26-7, Erythropoietin 25322-68-3, Polyethylene glycol 25775-90-0, Civamide 26009-03-0, Poly(glycolic acid) 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26100-51-6, Poly(lactic acid) 26124-68-5, Poly(glycolic acid) 34346-01-5, Glycolic acid-lactic acid copolymer 59112-80-0, C-Peptide 62229-50-9, Epidermal growth factor 81627-83-0, Macrophage colony-stimulating factor 89750-14-1, Glucagon-like peptide I 89750-15-2, Glucagon-likepeptide 2 113189-02-9, Blood coagulation factor VIII 143011-72-7, Granulocyte colony-stimulating factor 169494-85-3, Leptin 409108-20-9, Perfectamyl A 3108 409108-21-0, Cerestar 06090 409108-41-4, Reppal PSM 60U 409108-42-5, Reppal PSM 25  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bioglan Therapeutics Ab; WO 9920253 A1 1999 CAPLUS
- (2) Bruce, K; US 5455342 A 1995 CAPLUS
- (3) Michael, E; US 5792477 A 1998 CAPLUS
- (4) Rutgers University; WO 9900425 A1 1999 CAPLUS
- (5) Ulf, S; US 4713249 A 1987 CAPLUS

=> FIL STNGUIDE

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

40.69

TOTAL

SESSION

40.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.86	-5.86

FILE 'STNGUIDE' ENTERED AT 11:59:58 ON 21 FEB 2003  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Feb 14, 2003 (20030214/UP).

=>  
Connection closed by remote host

---Logging off of STN---

END

Unable to generate the STN prompt.  
Exiting the script...